Douglas LeeVP, Business Development & Licensing Head Digital & Data Science at Bayer U.S. Pharmaceuticals
Douglas Lee is Vice President, Business Development & Licensing at Bayer AG Pharmaceuticals (DAX: BAYN), where he leads the global function in digital and data science. Previously, he was Vice President, Strategy & Corporate Development at Samsung Strategy & Innovation Center, focusing on new business creation in digital health through incubation, investment and M&A, and Vice President, Strategy & Business Development of Global Services at Siemens Healthineers (DAX: SIE). Mr. Lee was Co-Founder and CEO of OrthoMEMS (and its AcuMEMS subsidiary), a medical technology company based on MEMS, and served as CEO of The Dr. Spock Company, a venture-backed consumer digital media company for children’s health. Concurrently, Mr. Lee was Managing Director of Premier Medical Partner Fund LP, a healthcare venture capital fund. Before Premier, he was CFO and Vice President of the new ventures and corporate business development group at Guidant Corporation (NYSE: GDT) and at publicly-traded Genelabs Technologies (NASDAQ: GNLB). Earlier in his career, Mr. Lee was an investment banker at Montgomery Securities, Goldman Sachs, and Kemper Securities. Mr. Lee has served as a board member of several venture-backed companies that successfully exited, including Atrionix (acquired by Johnson & Johnson), Durect Corporation (IPO: DRRX), Endotex Interventional Systems (acquired by Boston Scientiﬁc), and Icon Biosciences (acquired by Psivida). Mr. Lee earned an MBA from the University of Chicago and a BS in business administration from the University of California at Berkeley.